California Public Employees Retirement System Has $8.73 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

California Public Employees Retirement System reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 145,833 shares of the company's stock after selling 38,011 shares during the period. California Public Employees Retirement System owned 0.12% of Apellis Pharmaceuticals worth $8,730,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of APLS. Handelsbanken Fonder AB raised its stake in Apellis Pharmaceuticals by 31.4% in the 4th quarter. Handelsbanken Fonder AB now owns 22,600 shares of the company's stock valued at $1,353,000 after purchasing an additional 5,400 shares during the last quarter. abrdn plc acquired a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $10,119,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Apellis Pharmaceuticals by 43.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,123 shares of the company's stock valued at $1,205,000 after buying an additional 6,102 shares during the period. Sippican Capital Advisors boosted its position in Apellis Pharmaceuticals by 1.1% during the fourth quarter. Sippican Capital Advisors now owns 16,004 shares of the company's stock worth $958,000 after acquiring an additional 170 shares during the last quarter. Finally, Mackenzie Financial Corp purchased a new stake in Apellis Pharmaceuticals in the 4th quarter worth approximately $2,483,000. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Trading Down 0.1 %

Shares of Apellis Pharmaceuticals stock traded down $0.03 during trading hours on Friday, hitting $47.46. 1,106,743 shares of the company's stock traded hands, compared to its average volume of 1,535,888. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals, Inc. has a twelve month low of $19.83 and a twelve month high of $94.75. The stock has a 50 day simple moving average of $56.13 and a 200-day simple moving average of $57.38.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. Apellis Pharmaceuticals's quarterly revenue was up 545.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.50) EPS. As a group, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 18,681 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total transaction of $1,068,179.58. Following the transaction, the director now directly owns 173,998 shares in the company, valued at approximately $9,949,205.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Timothy Eugene Sullivan sold 1,431 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $96,978.87. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares in the company, valued at approximately $6,325,516.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director A. Sinclair Dunlop sold 18,681 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total value of $1,068,179.58. Following the sale, the director now directly owns 173,998 shares in the company, valued at $9,949,205.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 376,427 shares of company stock worth $23,169,639. Insiders own 7.50% of the company's stock.

Analyst Ratings Changes

APLS has been the subject of a number of recent analyst reports. UBS Group lifted their price objective on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a "buy" rating in a research report on Monday, March 4th. The Goldman Sachs Group upped their price objective on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a "buy" rating in a research note on Tuesday, January 9th. HC Wainwright reissued a "buy" rating and issued a $92.00 target price on shares of Apellis Pharmaceuticals in a research report on Friday, April 26th. Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a "hold" rating to a "buy" rating and upped their price target for the stock from $68.00 to $80.00 in a research report on Monday, February 5th. Finally, Mizuho cut their price target on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a "neutral" rating on the stock in a research note on Monday. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $77.40.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).